A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis

ConclusionSurprisingly, patients who are overweight or obese are more likely to obtain long-term clinical benefit in their psoriasis symptoms with infliximab therapy than patients who are normal weight.

http://link.springer.com/10.1007/s13555-020-00436-1

Source: Dermatology and Therapy - August 19, 2020 Category: Dermatology Source Type: research